New 2026 research reveals UC-MSC exosomes combined with low-intensity pulsed ultrasound and curcumin-hydrogel systems achieve remarkable burn wound healing — including MRSA-infected wounds — through autophagy regulation, anti-scarring mechanisms, and immunomodulation. Five landmark papers reviewed.
2026 patient guide to MSC therapy for Alzheimer’s disease: how it differs from lecanemab and donanemab, who is a candidate, what outcomes to expect, the 6 active clinical trials including NCT06775964 and the first MSC + antibody drug combination trial.
5 MSC and exosome trials for psoriasis have reported completion; three 2026 mechanistic studies reveal novel Ang1/Tie2 angiogenesis mechanisms, engineered exosome-nanoparticle platforms, and culture medium optimization for psoriasis-specific MSC potency.
A 2026 meta-analysis of 7 randomized trials confirms intradiscal MSC injections reduce chronic back pain and disability significantly. Meanwhile, bioengineered exosome therapies are redefining what cell-free disc regeneration looks like.
CRISPR-edited MSCs, iPSC-derived cells, combinatorial cell therapy, and exosome-based approaches are transforming PAD/CLI treatment. Six landmark 2026 papers and five active clinical trials reviewed for clinicians and researchers.
Pulmonary arterial hypertension kills half its patients within five years. 2026 research shows mesenchymal stem cells — especially HO-1-modified and mitochondria-primed MSCs — are reversing the vascular remodeling at the disease’s core. Here’s the science behind the breakthrough.
A 2026 Phase 1 trial showed that MSC-derived exosomes injected into the ear were safe and improved hearing in patients with sudden sensorineural hearing loss. Here’s what the breakthrough means and when it could be available.
Stem cell therapy prices range from $2,000 to $100,000 depending on where you go. Here’s what actually drives the cost, what’s included, and how Thailand compares to the US, Australia, and Europe in 2026.
MSC therapy is offering new hope for IBD patients who don’t respond to conventional biologics. Here’s what the 2026 clinical data shows.
PRP has its limits. For serious tendon and ligament injuries, stem cells are showing results PRP cannot match.
French 
English 
Chinese 
Russian